Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Prostate Cancer treatment details. Biologic therapy. Chemotherapy. University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, United States

Survival: 17.8 months
Toxicity Grade: 5
Treatments: Biologic therapy
Country: United States
City/State/Province: Los Angeles, CA
Hospital: University of Southern California Norris Comprehensive Cancer Center
Journal: Link
Date: 8/2013

This phase 3 study involved advanced castration-resistant prostate cancer patients who were divided into two separate treatment groups. Group A had 496 patients with a median age of 69 years. There were 498 patients in group B with a median age of 69 years.

Patients in group A were treated with the chemotherapy agent docetaxel.

Patients in group B were treated with docetaxel and the biologic therapy agent called atrasentan, which is an inhibitor of the endothelin receptor and may inhibit cancer metastases.

There were seven treatment-related deaths in group A due to respiratory failure, infection, heart failure, and skin toxicity.

There were three treatment-related deaths in group B due to bleeding and infection.

The median overall survival in groups A and B was 17.6 and 17.8 months, respectively.

This study was partially supported by Sanofi-Aventis and Abbott Laboratories.

Correspondence: Dr. David I Quinn; email:

E-mail to a Friend Email Physician More Information